The launch of the Catalyst® Pancreatic Lipase Test demonstrates IDEXX's Technology for Life strategy and will provide veterinarians with quantitative results at the point-of-care in less than 10 minutes WESTBROOK, Maine, June 4, 2024 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, announces the launch of the Catalyst® Pancreatic Lipase Test, a single-slide solution for canine and feline patients suspected of pancreatitis. With the innovative load-and-go ...

IDEXX Laboratories' (IDXX) business has been suffering due to complex macroeconomic conditions and unfavorable currency movement. The stock carries a Zacks Rank #4 (Sell) currently. Global macroeconomic conditions, including growing geopolitical complexities, supply chain disruptions leading to increases in the unit cost of raw materials, shortages of healthcare staff, fluctuations in foreign currency exchange rates and volatility in capital markets may continue to affect IDEXX's results of operations. Thes ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________. COMMISSION FILE NUMBER: 000-19271 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware ...

Fortune.com recently reported that artificial intelligence (AI) is helping the pet care industry cope with a chronic veterinary shortage. AI use cases could become far more prevalent for pets than humans in the near term due to fewer impediments such as privacy laws. That’s excellent news for AI pet stocks. Indeed, animal health innovation is accelerating in 2024. As an investor, it pays to be aware of trends in this consistently growing industry. The pet sector came into its own during the pandemic. Now po ...

Company Participants Conference Call Participants Operator IDEXX would like to preface the discussion today with a caution regarding forward-looking statements. Listeners are reminded that our discussion during the call will include forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those discussed today. During this call, we will be discussing certain financial measures not prepared in accordance with generally accepted accountin ...

IDEXX Laboratories, Inc. (IDXX) posted first-quarter 2024 earnings per share (EPS) of $2.81, up 10.2% year over year. The figure surpassed the Zacks Consensus Estimate by 4.9%.In the first quarter of 2024, comparable constant-currency EPS of $2.71 improved 8.8% year over year.Revenues in DetailFirst-quarter revenues increased 7.1% year over year (7% organically) to $964.1 million. However, the metric missed the Zacks Consensus Estimate by 0.1%.The year-over-year upside was primarily driven by the 7% reporte ...

For the quarter ended March 2024, Idexx Laboratories (IDXX) reported revenue of $964.1 million, up 7.1% over the same period last year. EPS came in at $2.81, compared to $2.55 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $965.43 million, representing a surprise of -0.14%. The company delivered an EPS surprise of +4.85%, with the consensus EPS estimate being $2.68.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- an ...

Idexx Laboratories (IDXX) came out with quarterly earnings of $2.81 per share, beating the Zacks Consensus Estimate of $2.68 per share. This compares to earnings of $2.55 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 4.85%. A quarter ago, it was expected that this Animal diagnostic and health care company would post earnings of $2.12 per share when it actually produced earnings of $2.32, delivering a surprise of 9.43%.Over t ...

Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: John Ravis, Investor Relations, 1-207-556-8155 IDEXX Laboratories Announces First Quarter Results ▪ Achieves first quarter revenue growth of 7% as reported and organic, supported by CAG Diagnostics recurring revenue growth of 7% as reported and organic ▪ Solid growth supported by continued benefits from IDEXX execution drivers including double-digit year-over-year installed base growth across global premium instrument platforms ▪ Delivers EPS of $2.81, reflecting ...

Analysts on Wall Street project that Idexx Laboratories (IDXX) will announce quarterly earnings of $2.68 per share in its forthcoming report, representing an increase of 5.1% year over year. Revenues are projected to reach $966.4 million, increasing 7.4% from the same quarter last year.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Before a company an ...